Literature DB >> 9006799

Lp(a) concentrations are related to plasma lipid concentrations.

D L Rainwater1.   

Abstract

Lp(a) concentrations are controlled primarily by genetic variation at LPA, the locus encoding the unique protein apo(a). However, the high heritability is in part a consequence of nearly a 1000-fold range of Lp(a) concentrations found in healthy individuals. As determined by use of siblings genetically identical-by-descent at the LPA locus, there is substantial within-genotype variation in Lp(a) concentrations (ranges averaged about 58% of mean values for 87 sibling groups). This within-genotype variation could affect risk of CVD for nearly 15% of individuals in a population. Furthermore, Lp(a) concentrations are significantly and independently correlated with two key indicators of lipoprotein metabolism, plasma cholesterol and triglyceride concentrations. Taken together, these data suggest that it is both possible and desirable to develop strategies for modifying Lp(a) concentrations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9006799     DOI: 10.1016/s0021-9150(96)05922-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  4 in total

1.  Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.

Authors:  Louise A Donnelly; Natalie R van Zuydam; Kaixin Zhou; Roger Tavendale; Fiona Carr; Anke H Maitland-van der Zee; Maarten Leusink; Anthonius de Boer; Pieter A Doevendans; Folkert W Asselbergs; Andrew D Morris; Ewan R Pearson; Olaf H Klungel; Alex S F Doney; Colin N A Palmer
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

2.  Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels.

Authors:  Wensheng Lu; Yu-Ching Cheng; Keping Chen; Hong Wang; Glenn S Gerhard; Christopher D Still; Xin Chu; Rongze Yang; Ankita Parihar; Jeffrey R O'Connell; Toni I Pollin; Eduardo Angles-Cano; Michael J Quon; Braxton D Mitchell; Alan R Shuldiner; Mao Fu
Journal:  Hum Mol Genet       Date:  2015-01-09       Impact factor: 6.150

3.  Variations of lipoprotein(a) levels in the metabolic syndrome: a report from the Maracaibo City Metabolic Syndrome Prevalence Study.

Authors:  Valmore Bermúdez; Joselyn Rojas; Juan Salazar; Luis Bello; Roberto Añez; Alexandra Toledo; Maricarmen Chacín; Miguel Aguirre; Marjorie Villalobos; Mervin Chávez; María Sofía Martínez; Wheeler Torres; Yaquelin Torres; José Mejías; Edgardo Mengual; Liliana Rojas; Milagro Sánchez de Rosales; Ana Quevedo; Raquel Cano; Mayela Cabrera; Rafael París; Adonías Lubo; María Montiel; Climaco Cano
Journal:  J Diabetes Res       Date:  2013-04-22       Impact factor: 4.011

4.  Effect of Nandrolone Decanoate on serum lipoprotein (a) and its isoforms in hemodialysis patients.

Authors:  Amir Ghorbanihaghjo; Hassan Argani; Mohammad Rohbaninoubar; Nadereh Rashtchizadeh
Journal:  Lipids Health Dis       Date:  2004-06-29       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.